@article {Gerschutz377, author = {Gregory P. Gerschutz and Deepak L. Bhatt}, title = {The CURE trial: Using clopidogrel in acute coronary syndromes without ST-segment elevation}, volume = {69}, number = {5}, pages = {377--385}, year = {2002}, publisher = {Cleveland Clinic Journal of Medicine}, abstract = {In a large, randomized, placebo-controlled trial in centers that use a conservative approach to acute coronary syndromes, the antiplatelet drug clopidogrel (Plavix) decreased the rate of the combined end point of cardiovascular death, nonfatal myocardial infarction, or stroke by 20\% in patients presenting with acute coronary syndromes without ST-segment elevation. The benefit was at the cost of an increase in bleeding, however. This strategy may need to be tailored in centers that use a more aggressive treatment strategy of early angiography and revascularization.}, issn = {0891-1150}, URL = {https://www.ccjm.org/content/69/5/377}, eprint = {https://www.ccjm.org/content/69/5/377.full.pdf}, journal = {Cleveland Clinic Journal of Medicine} }